JP5606438B2 - 抗血管新生療法を受容可能な被験体の同定 - Google Patents

抗血管新生療法を受容可能な被験体の同定 Download PDF

Info

Publication number
JP5606438B2
JP5606438B2 JP2011519175A JP2011519175A JP5606438B2 JP 5606438 B2 JP5606438 B2 JP 5606438B2 JP 2011519175 A JP2011519175 A JP 2011519175A JP 2011519175 A JP2011519175 A JP 2011519175A JP 5606438 B2 JP5606438 B2 JP 5606438B2
Authority
JP
Japan
Prior art keywords
amount
subject
angiogenic therapy
cardiac troponin
troponin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2011519175A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011528797A5 (enExample
JP2011528797A (ja
Inventor
ヘス，ゲオルク
ホルシュ，アンドレア
ズドゥネク，ディートマル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40162929&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP5606438(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of JP2011528797A publication Critical patent/JP2011528797A/ja
Publication of JP2011528797A5 publication Critical patent/JP2011528797A5/ja
Application granted granted Critical
Publication of JP5606438B2 publication Critical patent/JP5606438B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4712—Muscle proteins, e.g. myosin, actin, protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Brain natriuretic peptide [BNP, proBNP]; Cardionatrin; Cardiodilatin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2011519175A 2008-07-23 2009-07-23 抗血管新生療法を受容可能な被験体の同定 Active JP5606438B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08161014.9 2008-07-23
EP08161014 2008-07-23
PCT/EP2009/059505 WO2010010153A1 (en) 2008-07-23 2009-07-23 Identification of subjects being susceptible to anti-angiogenesis therapy

Publications (3)

Publication Number Publication Date
JP2011528797A JP2011528797A (ja) 2011-11-24
JP2011528797A5 JP2011528797A5 (enExample) 2012-01-12
JP5606438B2 true JP5606438B2 (ja) 2014-10-15

Family

ID=40162929

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011519175A Active JP5606438B2 (ja) 2008-07-23 2009-07-23 抗血管新生療法を受容可能な被験体の同定

Country Status (5)

Country Link
US (1) US9983213B2 (enExample)
EP (1) EP2321651B1 (enExample)
JP (1) JP5606438B2 (enExample)
ES (1) ES2644723T3 (enExample)
WO (1) WO2010010153A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3485908B1 (en) 2009-10-16 2021-08-18 Mereo BioPharma 5, Inc. Therapeutic combination and use of dll4 antagonist antibodies and anti-hypertensive agents
US10260097B2 (en) 2011-06-02 2019-04-16 Almac Diagnostics Limited Method of using a gene expression profile to determine cancer responsiveness to an anti-angiogenic agent
TWI583699B (zh) 2011-09-23 2017-05-21 安可美德藥物股份有限公司 Ｖｅｇｆ／ｄｌｌ４結合劑類及彼等之用途
CA2889638A1 (en) * 2012-10-31 2014-05-08 Oncomed Pharmaceuticals, Inc. Methods and monitoring of treatment with a dll4 antagonist
HK1214633A1 (zh) 2012-12-03 2016-07-29 Almac Diagnostics Limited 癌症的分子诊断测试
GB201409479D0 (en) 2014-05-28 2014-07-09 Almac Diagnostics Ltd Molecular diagnostic test for cancer
EP3212233B1 (en) 2014-10-31 2020-06-24 Oncomed Pharmaceuticals, Inc. Combination therapy for treatment of disease
US11339213B2 (en) 2015-09-23 2022-05-24 Mereo Biopharma 5, Inc. Methods and compositions for treatment of cancer

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744101A (en) 1989-06-07 1998-04-28 Affymax Technologies N.V. Photolabile nucleoside protecting groups
US6582959B2 (en) 1991-03-29 2003-06-24 Genentech, Inc. Antibodies to vascular endothelial cell growth factor
GB9211686D0 (en) 1992-06-03 1992-07-15 Medisinsk Innovation A S Chemical compounds
KR100335584B1 (ko) 1992-10-28 2002-11-29 제넨테크, 인코포레이티드 혈관내피세포성장인자에대한길항제
DE69829891T2 (de) 1997-04-07 2005-10-06 Genentech, Inc., South San Francisco Anti-VEGF Antikörper
US20020032315A1 (en) 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
WO2000054770A1 (en) * 1999-03-15 2000-09-21 Boston Life Sciences, Inc. Pharmaceutical compositions comprising troponin subunits, fragments and homologs thereof and methods of their use to inhibit angiogenesis
US6703020B1 (en) 1999-04-28 2004-03-09 Board Of Regents, The University Of Texas System Antibody conjugate methods for selectively inhibiting VEGF
US20020051978A1 (en) * 2000-02-17 2002-05-02 Roth Frederick P. Methods and compositions for the identification, assessment, prevention and therapy of human cancers
US7632647B2 (en) 2001-04-13 2009-12-15 Biosite Incorporated Use of B-type natriuretic peptide as a prognostic indicator in acute coronary syndromes
EP1322957B1 (en) 2001-05-04 2009-08-12 Biosite Incorporated Diagnostic markers of acute coronary syndromes and methods of use thereof
RS20150135A1 (sr) 2003-05-30 2015-08-31 Genentech Inc. Tretman sa anti-vegf antitelima
WO2005044853A2 (en) 2003-11-01 2005-05-19 Genentech, Inc. Anti-vegf antibodies
ES2421556T3 (es) * 2004-06-15 2013-09-03 Hoffmann La Roche Utilización de hormonas cardíacas para diagnosticar el riesgo de sufrir complicaciones cardiovasculares como consecuencia de medicamentos cardiotóxicos
US7939267B2 (en) * 2004-11-04 2011-05-10 Laboratory Corporation Of America Holdings Detection of activation of endothelial cells as surrogate marker for angiogenesis
CA2595794A1 (en) * 2005-01-24 2006-07-27 F. Hoffmann-La Roche Ag The use of cardiac hormones for assessing a cardiovascular risk with respect to the administration of anti-inflammatory drugs
AU2006279658A1 (en) * 2005-08-12 2007-02-22 Regeneron Pharmaceuticals, Inc. Treatment of diseases by subcutaneous administration of a VEGF antagonist
AU2007233320B2 (en) 2006-04-04 2013-12-12 Singulex, Inc. Highly sensitive system and methods for analysis of troponin
EP1887361A1 (en) * 2006-08-07 2008-02-13 Bio-Rad Pasteur Method for the prediction of vascular events
EP1890154B1 (en) 2006-08-16 2012-07-04 F. Hoffmann-La Roche AG Cardiac troponin as an indicator of advanced coronary artery disease
CA2666709A1 (en) 2006-11-10 2008-05-29 Genentech, Inc. Method for treating age-related macular degeneration
JP5306218B2 (ja) * 2006-11-21 2013-10-02 エフ．ホフマン−ラ ロシュ アーゲー トロポニンＴおよびＮＴ−ｐｒｏＢＮＰの検出に基づく慢性動脈疾患での診断および治療的アプローチの最適化のための手段および方法
JP2011528798A (ja) 2008-07-23 2011-11-24 エフ．ホフマン−ラ ロシュ アーゲー 抗血管形成療法のモニター

Also Published As

Publication number Publication date
EP2321651A1 (en) 2011-05-18
ES2644723T3 (es) 2017-11-30
US20110113864A1 (en) 2011-05-19
JP2011528797A (ja) 2011-11-24
WO2010010153A1 (en) 2010-01-28
EP2321651B1 (en) 2017-08-23
US9983213B2 (en) 2018-05-29

Similar Documents

Publication Publication Date Title
US11719710B2 (en) GDF-15 and/or troponin T for predicting kidney failure in heart surgery patients
JP2011523051A (ja) １型糖尿病におけるバイオマーカーとしてのｇｄｆ−１５
US9983213B2 (en) Identification of subjects being susceptible to anti-angiogenesis therapy
JP5198565B2 (ja) 心疾患に関連する又は関連しないｇｄｆ−１５の上昇の区別のための手段及び方法
JP2008102129A (ja) 急性肺塞栓症用生化学マーカー
US20110113865A1 (en) Using cardiac troponin for monitoring anti-angiogenesis therapy
JP2010510481A (ja) トロポニンＴおよびＮＴ−ｐｒｏＢＮＰの検出に基づく慢性動脈疾患での診断および治療的アプローチの最適化のための手段および方法
JP5369118B2 (ja) バイオマーカーｐｌｇｆを用いてアテローム性動脈硬化負荷を決定する手段及び方法
EP2597466A1 (en) Means and methods for proSP-B based diagnosis of alveolar damage in pulmonary hypertension patients
EP2383579A1 (en) sFlt-1, cardiac troponins and natriuretic peptides in the recognition of therapy with HER-2 inhibitors
US8440463B2 (en) Predicting renal failure in diabetes patients based on placental growth factor and soluble FLT-1
EP2916134B1 (en) Use of Seprase for differential diagnosis of acute dyspnea
EP2037278A1 (en) Vascular markers in the remodelling of cardiac injury
US20100086946A1 (en) Plgf, flt1 and endoglin for diagnosing angiogenic status in coronary artery disease
EP2508890A1 (en) CAIX based diagnosis of heart failure

Legal Events

Date Code Title Description
A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20120824

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120904

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121203

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130924

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131224

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20140729

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140826

R150 Certificate of patent or registration of utility model

Ref document number: 5606438

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250